Compugen's Q1 Loss up 18 Percent as It Ramps Up Commercialization Efforts

The company's general expenses and R&D costs rose for the first quarter of 2010, while sales were negligible, but it plans to 'substantially' increase future sales efforts.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories